Furthermore, ERAP2 expression is altered in first trimester placentas of women destined to develop preeclampsia.

A Cork-based biotechnology company has secured €2 million in funding to develop a product to identify whether women could develop preeclampsia.

Among women who did develop preeclampsia in their first pregnancy, 20.1% were overweight and 11.8% were obese.

However, women with Alport's syndrome can have an accelerated form of their disease during pregnancy with worsening of kidney function and can also develop preeclampsia.

A total of 67,273 women, or 4.9%, developed preeclampsia during at least one pregnancy, and 410 women developed end-stage kidney disease.